{"protocolSection":{"identificationModule":{"nctId":"NCT00000378","orgStudyIdInfo":{"id":"#3105"},"secondaryIdInfos":[{"id":"R01MH055716","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R01MH055716"}],"organization":{"fullName":"New York State Psychiatric Institute","class":"OTHER"},"briefTitle":"Antidepressant Treatment of Melancholia in Late Life","officialTitle":"Antidepressant Treatment of Melancholia in Late :Ife"},"statusModule":{"statusVerifiedDate":"2008-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"1997-07"},"primaryCompletionDateStruct":{"date":"2002-06","type":"ACTUAL"},"completionDateStruct":{"date":"2002-06","type":"ACTUAL"},"studyFirstSubmitDate":"1999-11-02","studyFirstSubmitQcDate":"1999-11-02","studyFirstPostDateStruct":{"date":"1999-11-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-04-02","resultsFirstSubmitQcDate":"2015-04-17","resultsFirstPostDateStruct":{"date":"2015-04-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-10-06","lastUpdatePostDateStruct":{"date":"2015-10-07","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"New York State Psychiatric Institute","class":"OTHER"},"collaborators":[{"name":"National Institute of Mental Health (NIMH)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression.\n\nSSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients.\n\nPatients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication.\n\nAn individual may be eligible for this study if he/she:\n\nHas unipolar major depression (with some exceptions) and is over 60 years old.","detailedDescription":"To compare the efficacy and safety of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who meet Diagnostic and Statistical Manuel-IV criteria for unipolar major depression, excluding patients who meet criteria for psychotic or atypical subtype. To test the hypothesis that medication condition interacts with diagnostic subtype (melancholic vs non-melancholic) in determining antidepressant response. To examine the roles of symptom severity and alternative diagnostic subtyping in contributing to this pattern.\n\nSSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for depressed patients with melancholia. This issue is of particular concern in late-life major depression. SSRIs have important safety advantages with respect to overdose and a benign cardiovascular profile. Furthermore, the SSRIs do not have significant anticholinergic effects, and appear to be better tolerated than the TCAs. Perhaps most important, the SSRIs currently are prescribed widely as the medication treatment of first choice for major depression in late life. Therefore, if it were determined that SSRIs are considerably less effective than TCAs in the treatment of melancholia in the elderly, there would be significant ramifications for clinical practice.\n\nRandomization to sertraline (a SSRI) or nortriptyline (a TCA) is stratified by the presence or absence of melancholia. Outcome measures for the 12-week acute phase include clinician and patient ratings of symptoms, side effects, and an evaluation of the health-related quality of life (HRQOL). At the end of the acute treatment phase, patients who meet criteria for clinical response participate in a 6-month continuation phase."},"conditionsModule":{"conditions":["Depression","Melancholia"],"keywords":["Aged","Antidepressive Agents, Tricyclic","Depression","Female","Human","Male","Middle Age","Nortriptyline","Sertraline","Serotonin Uptake Inhibitors","Antidepressive Agents, Tricyclic -- *therapeutic use","Antidepressive Agents, Tricyclic -- adverse effects","Depression -- *drug therapy","Nortriptyline -- *therapeutic use","Nortriptyline -- adverse effects","Sertraline -- *therapeutic use","Sertraline -- adverse effects","Serotonin Uptake Inhibitors -- *therapeutic use","Serotonin Uptake Inhibitors -- adverse effects"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":110,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"sertaline","type":"ACTIVE_COMPARATOR","description":"patients randomized to sertraline 12 week trial does up to 200mgs","interventionNames":["Drug: Sertraline"]},{"label":"nortriptyline","type":"ACTIVE_COMPARATOR","description":"patients randomized to nortriptyline dose adjusted to therapeutic level","interventionNames":["Drug: Nortriptyline"]}],"interventions":[{"type":"DRUG","name":"Sertraline","description":"12 week trial dose up to 200mgs","armGroupLabels":["sertaline"]},{"type":"DRUG","name":"Nortriptyline","description":"12 week trial dose adjusted to therapeutic level","armGroupLabels":["nortriptyline"],"otherNames":["nortiptyline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"HAMILTON Rating Scale for DEPRESSION Range","description":"Hamilton scale range 0-40, values below 7 are considered normal. the higher the number the more severe the depression weekly assessments, The primary outcome is a comparison of the baseline Hamilton to the 12 week measurement","timeFrame":"BASELINE COMPARED TO 12 WEEK MEASUREMENT"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\-\n\nPatients must have:\n\nUnipolar major depression (per Diagnostic and Statistical Manuel-IV criteria) with or without melancholia.\n\nExclusion Criteria:\n\n\\-\n\nPatients with the following symptoms or conditions are excluded:\n\nPsychotic or atypical subtype of unipolar major depression.","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","maximumAge":"95 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Steven P. Roose, MD","affiliation":"New York State Psychiatric Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"1051 Riverside Drive","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Sertaline","description":"patients randomized to sertraline 12 week trial does up to 200mgs\n\nSertraline: 12 week trial dose up to 200mgs"},{"id":"FG001","title":"Nortriptyline","description":"patients randomized to nortriptyline dose adjusted to therapeutic level\n\nNortriptyline: 12 week trial dose adjusted to therapeutic level"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"52"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"38"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"14"}]}],"dropWithdraws":[{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"14"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Sertaline","description":"patients randomized to sertraline 12 week trial does up to 200mgs\n\nSertraline: 12 week trial dose up to 200mgs"},{"id":"BG001","title":"Nortriptyline","description":"patients randomized to nortriptyline dose adjusted to therapeutic level\n\nNortriptyline: 12 week trial dose adjusted to therapeutic level"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"110"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"98"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"64"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"46"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"110"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"HAMILTON Rating Scale for DEPRESSION Range","description":"Hamilton scale range 0-40, values below 7 are considered normal. the higher the number the more severe the depression weekly assessments, The primary outcome is a comparison of the baseline Hamilton to the 12 week measurement","populationDescription":"intent to treat analysis","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"BASELINE COMPARED TO 12 WEEK MEASUREMENT","groups":[{"id":"OG000","title":"Sertaline","description":"patients randomized to sertraline 12 week trial does up to 200mgs\n\nSertraline: 12 week trial dose up to 200mgs"},{"id":"OG001","title":"Nortriptyline","description":"patients randomized to nortriptyline dose adjusted to therapeutic level\n\nNortriptyline: 12 week trial dose adjusted to therapeutic level"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"52"}]}],"classes":[{"title":"BASELINE","categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":"6.6"},{"groupId":"OG001","value":"27.1","spread":"4.4"}]}]},{"title":"12 WEEK DATA","categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"8.3"},{"groupId":"OG001","value":"8.4","spread":"7.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"logistic regression and mixed effects model","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.05","pValueComment":"actual calculation","statisticalMethod":"Regression, Logistic","ciNumSides":"TWO_SIDED"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Sertaline","description":"patients randomized to sertraline 12 week trial does up to 200mgs\n\nSertraline: 12 week trial dose up to 200mgs","seriousNumAffected":0,"seriousNumAtRisk":58,"otherNumAffected":2,"otherNumAtRisk":58},{"id":"EG001","title":"Nortriptyline","description":"patients randomized to nortriptyline dose adjusted to therapeutic level\n\nNortriptyline: 12 week trial dose adjusted to therapeutic level","seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":4,"otherNumAtRisk":52}],"otherEvents":[{"term":"orthostatic hypotension","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":52}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Steven Roose MD","organization":"New York State Psychiatric Institute","email":"spr2@columbia.edu","phone":"646-774-8661"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003863","term":"Depression"},{"id":"D003866","term":"Depressive Disorder"}],"ancestors":[{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D020280","term":"Sertraline"},{"id":"D009661","term":"Nortriptyline"}],"ancestors":[{"id":"D015057","term":"1-Naphthylamine"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D009281","term":"Naphthalenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D003986","term":"Dibenzocycloheptenes"},{"id":"D001567","term":"Benzocycloheptenes"}]}},"hasResults":true}